scholarly article | Q13442814 |
P50 | author | J Gregory Cairncross | Q114727084 |
Rebecca Betensky | Q42290664 | ||
P2093 | author name string | H Sasaki | |
D N Louis | |||
Y Ino | |||
M C Zlatescu | |||
P2860 | cites work | DMBT1, a new member of the SRCR superfamily, on chromosome 10q25.3-26.1 is deleted in malignant brain tumours | Q24310338 |
TEP1, encoded by a candidate tumor suppressor locus, is a novel protein tyrosine phosphatase regulated by transforming growth factor beta | Q24310394 | ||
Human transcription-repair coupling factor CSB/ERCC6 is a DNA-stimulated ATPase but is not a helicase and does not disrupt the ternary transcription complex of stalled RNA polymerase II | Q24314310 | ||
Molecular analysis of mutations in the CSB (ERCC6) gene in patients with Cockayne syndrome | Q24538671 | ||
Lack of DMBT1 expression in oesophageal, gastric and colon cancers | Q24650252 | ||
Crystal structure of the PTEN tumor suppressor: implications for its phosphoinositide phosphatase activity and membrane association | Q27620298 | ||
PTEN gene transfer in human malignant glioma: sensitization to irradiation and CD95L-induced apoptosis. | Q55476772 | ||
Molecular analysis of two putative tumour suppressor genes, PTEN and DMBT, which have been implicated in glioblastoma multiforme disease progression. | Q55477358 | ||
Distinct patterns of deletion on 10p and 10q suggest involvement of multiple tumor suppressor genes in the development of astrocytic gliomas of different malignancy grades. | Q55477778 | ||
Frequent inactivation of PTEN/MMAC1 in primary prostate cancer | Q57240096 | ||
DMBT1 encodes a protein involved in the immune defense and in epithelial differentiation and is highly unstable in cancer | Q57326209 | ||
Frequency of homozygous deletion at p16/CDKN2 in primary human tumours | Q71721193 | ||
MTS1/CDKN2 gene mutations are rare in primary human astrocytomas with allelic loss of chromosome 9p | Q72529989 | ||
PTEN, a putative protein tyrosine phosphatase gene mutated in human brain, breast, and prostate cancer | Q27860985 | ||
Alterations in the CSB gene in three Italian patients with the severe form of Cockayne syndrome (CS) but without clinical photosensitivity | Q28141024 | ||
Localization of the nucleotide excision repair gene ERCC6 to human chromosome 10q11-q21 | Q28182048 | ||
ERCC6, a member of a subfamily of putative helicases, is involved in Cockayne's syndrome and preferential repair of active genes | Q28213725 | ||
MMAC1/PTEN mutations in primary tumor specimens and tumor cell lines | Q28256046 | ||
A highly conserved processed PTEN pseudogene is located on chromosome band 9p21 | Q28273178 | ||
Identification of a candidate tumour suppressor gene, MMAC1, at chromosome 10q23.3 that is mutated in multiple advanced cancers | Q28306997 | ||
Defective transcription-coupled repair in Cockayne syndrome B mice is associated with skin cancer predisposition | Q28585729 | ||
New insights into tumor suppression: PTEN suppresses tumor formation by restraining the phosphoinositide 3-kinase/AKT pathway | Q29616144 | ||
Mutation nomenclature extensions and suggestions to describe complex mutations: a discussion | Q29616531 | ||
The multiple roles of PTEN in tumor suppression | Q33849727 | ||
The genomic structure of the DMBT1 gene: evidence for a region with susceptibility to genomic instability | Q33883544 | ||
Molecular subtypes of anaplastic oligodendroglioma: implications for patient management at diagnosis. | Q33942929 | ||
Chemotherapy for anaplastic oligodendroglioma. National Cancer Institute of Canada Clinical Trials Group | Q34059674 | ||
Chromosome 10 deletion mapping in human gliomas: a common deletion region in 10q25. | Q34313328 | ||
Molecular genetic aspects of oligodendrogliomas including analysis by comparative genomic hybridization | Q35787686 | ||
Deletion mapping of gliomas suggest the presence of two small regions for candidate tumor-suppressor genes in a 17-cM interval on chromosome 10q. | Q36801269 | ||
A (CA)n dinucleotide repeat assay for evaluating loss of allelic heterozygosity in small and archival human brain tumor specimens. | Q38487094 | ||
A tiger behind many doors: multiple genetic pathways to malignant glioma | Q40372189 | ||
Expression of DMBT1, a candidate tumor suppressor gene, is frequently lost in lung cancer | Q40959040 | ||
Allelic deletion analyses of MMAC/PTEN and DMBT1 loci in gliomas: relationship to prognostic significance. | Q44043105 | ||
PTEN gene mutations are seen in high-grade but not in low-grade gliomas. | Q44846579 | ||
MMAC1/PTEN inhibits cell growth and induces chemosensitivity to doxorubicin in human bladder cancer cells | Q45872881 | ||
Suppression of tumor growth in vivo by local and systemic 90K level increase | Q46143007 | ||
PTEN mutations in gliomas and glioneuronal tumors. | Q47995275 | ||
Successful chemotherapy for recurrent malignant oligodendroglioma | Q48090619 | ||
Localization of common deletion regions on 1p and 19q in human gliomas and their association with histological subtype | Q48144051 | ||
Differential expression of MMAC/PTEN in glioblastoma multiforme: relationship to localization and prognosis. | Q48230264 | ||
Mutational analysis of the PTEN gene in gliomas: molecular and pathological correlations | Q48252490 | ||
Specific genetic predictors of chemotherapeutic response and survival in patients with anaplastic oligodendrogliomas | Q48374829 | ||
Analysis of PTEN/MMAC1 alterations in aerodigestive tract tumors. | Q48544624 | ||
Mutation of the PTEN (MMAC1) tumor suppressor gene in a subset of glioblastomas but not in meningiomas with loss of chromosome arm 10q. | Q48566471 | ||
Somatic mutations of PTEN in glioblastoma multiforme | Q48618632 | ||
New deletion in low-grade oligodendroglioma at the glioblastoma suppressor locus on chromosome 10q25-26. | Q48636243 | ||
Improving diagnostic accuracy and interobserver concordance in the classification and grading of primary gliomas | Q48755711 | ||
Malignant astrocytomas with homozygous CDKN2/p16 gene deletions have higher Ki-67 proliferation indices | Q48910147 | ||
PTEN mutation in endometrial cancers is associated with favorable clinical and pathologic characteristics. | Q53427839 | ||
Analysis of oncogene and tumor suppressor gene alterations in pediatric malignant astrocytomas reveals reduced survival for patients with PTEN mutations. | Q55476256 | ||
Mutational profile of the PTEN gene in primary human astrocytic tumors and cultivated xenografts. | Q55476495 | ||
P433 | issue | 1 | |
P407 | language of work or name | English | Q1860 |
P921 | main subject | oligodendroglioma | Q1318384 |
P304 | page(s) | 359-367 | |
P577 | publication date | 2001-07-01 | |
P1433 | published in | The American Journal of Pathology | Q4744259 |
P1476 | title | PTEN is a target of chromosome 10q loss in anaplastic oligodendrogliomas and PTEN alterations are associated with poor prognosis | |
P478 | volume | 159 |
Q55463020 | Analysis of DNA repair gene polymorphisms and survival in low-grade and anaplastic gliomas. |
Q35804765 | Aptamer targeting EGFRvIII mutant hampers its constitutive autophosphorylation and affects migration, invasion and proliferation of glioblastoma cells |
Q34203979 | Biology, genetics and imaging of glial cell tumours |
Q36089590 | CNS Anticancer Drug Discovery and Development Conference White Paper. |
Q55466552 | Chromosomal alterations in oligodendroglial tumours over multiple surgeries: is tumour progression associated with change in 1p/19q status? |
Q48217296 | Clinical and Molecular Prognostic Factors for Long-Term Survival of Patients with Glioblastomas in Single-Institutional Consecutive Cohort |
Q48125887 | Clinical utility of fluorescence in situ hybridization (FISH) in morphologically ambiguous gliomas with hybrid oligodendroglial/astrocytic features |
Q37316986 | Combination therapy for malignant glioma based on PTEN status |
Q36234884 | Contribution of 1p, 19q, 9p and 10q Automated Analysis by FISH to the Diagnosis and Prognosis of Oligodendroglial Tumors According to WHO 2016 Guidelines |
Q45900892 | Correlation among pathology, genetic and epigenetic profiles, and clinical outcome in oligodendroglial tumors. |
Q37301207 | Epigenetic markers in human gliomas: prospects for therapeutic intervention |
Q33984130 | Extracranial skeletal metastasis in anaplastic oligodendroglioma: case report and review of the literature |
Q91732486 | GATAD1 gene amplification promotes glioma malignancy by directly regulating CCND1 transcription |
Q35001574 | Genetic alterations and signaling pathways in the evolution of gliomas |
Q55471652 | Genetic alterations of phosphoinositide 3-kinase subunit genes in human glioblastomas. |
Q34796547 | Genetic and epigenetic alterations in primary-progressive paired oligodendroglial tumors. |
Q48871005 | Genetic characterization of adult infratentorial gliomas |
Q35790152 | Glioma test array for use with formalin-fixed, paraffin-embedded tissue: array comparative genomic hybridization correlates with loss of heterozygosity and fluorescence in situ hybridization |
Q34518902 | Histopathological-molecular genetic correlations in referral pathologist-diagnosed low-grade "oligodendroglioma". |
Q51825686 | Homozygous 10q23/PTEN deletion and its impact on outcome in glioblastoma: a prospective translational study on a uniformly treated cohort of adult patients. |
Q52334523 | Identification of a PTEN mutation with reduced protein stability, phosphatase activity, and nuclear localization in Hong Kong patients with autistic features, neurodevelopmental delays, and macrocephaly. |
Q48280759 | Identification of genomic aberrations associated with shorter overall survival in patients with oligodendroglial tumors |
Q37355478 | Identification of two contiguous minimally deleted regions on chromosome 1p36.31-p36.32 in oligodendroglial tumours |
Q55457239 | Imaging scoring systems for preoperative molecular diagnoses of lower-grade gliomas. |
Q48505514 | Immunohistochemical markers for prognosis of oligodendroglial neoplasms |
Q48025289 | Immunolocalization of the oligodendrocyte transcription factor 1 (Olig1) in brain tumors |
Q48172557 | Loss of heterozygosity for loci on chromosome arms 1p and 10q in oligodendroglial tumors: relationship to outcome and chemosensitivity |
Q35945582 | MicroRNA-1908 functions as a glioblastoma oncogene by suppressing PTEN tumor suppressor pathway |
Q34468260 | Molecular biology of oligodendroglial tumors |
Q33214806 | Molecular classification of human gliomas using matrix-based comparative genomic hybridization |
Q37427424 | Molecular neuropathology of gliomas |
Q48874973 | Molecular pathology and clinical characteristics of oligodendroglial neoplasms |
Q37350203 | Molecular profiling of oligodendrogliomas: impact on prognosis, treatment, and future directions |
Q36140650 | Molecular-genetic and clinical characteristics of gliomas with astrocytic appearance and total 1p19q loss in a single institutional consecutive cohort |
Q47598180 | Molecular-genetic and clinicopathological prognostic factors in patients with gliomas showing total 1p19q loss: gain of chromosome 19p and histological grade III negatively correlate with patient's prognosis |
Q48879540 | Mutations of the PIK3CA gene are rare in human glioblastoma |
Q36187046 | Novel therapeutics in adult malignant brain gliomas |
Q36272041 | Oligodendroglioma: impact of molecular biology on its definition, diagnosis and management |
Q35063647 | Oligodendroglioma: toward molecular definitions in diagnostic neuro-oncology |
Q35105809 | Oligodendrogliomas: An update on basic and clinical research |
Q37808385 | PI3Kinase signaling in glioblastoma |
Q48591255 | PIK3CA mutations in oligodendroglial tumours. |
Q92702101 | PTEN as a Prognostic/Predictive Biomarker in Cancer: An Unfulfilled Promise? |
Q39640325 | PTEN gene mutations correlate to poor prognosis in glioma patients: a meta-analysis |
Q35868124 | Pathology and molecular genetics of oligodendroglial tumors |
Q48298546 | Pediatric oligodendrogliomas: a study of molecular alterations on 1p and 19q using fluorescence in situ hybridization. |
Q45006311 | Phase I/pharmacokinetic study of CCI-779 in patients with recurrent malignant glioma on enzyme-inducing antiepileptic drugs. |
Q46410598 | Phase II study of CCI-779 in patients with recurrent glioblastoma multiforme. |
Q44768519 | Prognostic value of 1p, 19q, 9p, 10q, and EGFR-FISH analyses in recurrent oligodendrogliomas |
Q34707865 | Pten signaling in gliomas |
Q85200112 | Rapid spontaneous regression of multicentric infantile myofibromatosis in the posterior fossa and lumbar vertebra |
Q34145096 | Rare mutations of the DMBT1 gene in human astrocytic gliomas |
Q48842295 | Recurrent PIK3CA mutations in rosette-forming glioneuronal tumor |
Q35140496 | Relationships between PTEN gene mutations and prognosis in glioma: a meta-analysis |
Q61829495 | Small cell astrocytoma: An aggressive variant that is clinicopathologically and genetically distinct from anaplastic oligodendroglioma |
Q34332857 | Spatial and temporal evolution of distal 10q deletion, a prognostically unfavorable event in diffuse low-grade gliomas |
Q24657924 | The PTEN-regulating microRNA miR-26a is amplified in high-grade glioma and facilitates gliomagenesis in vivo |
Q40596882 | The alteration of PTEN tumor suppressor expression and its association with the histopathological features of human primary hepatocellular carcinoma |
Q35634042 | The importance of 10q status in an outcomes-based comparison between 1p/19q fluorescence in situ hybridization and polymerase chain reaction-based microsatellite loss of heterozygosity analysis of oligodendrogliomas |
Q33921072 | The pathobiology of glioma tumors |
Q54649513 | The prognostic impact of histology and 1p/19q status in anaplastic oligodendroglial tumors. |
Q54752976 | Tumour necrosis and microvascular proliferation are associated with 9p deletion and CDKN2A alterations in 1p/19q-deleted oligodendrogliomas. |
Q55465124 | [Identification of genetic alterations by multiple ligation-dependent probe amplification (MLPA) analysis in oligodendrogliomas]. |
Q38973879 | miR-106b is overexpressed in medulloblastomas and interacts directly with PTEN. |
Search more.